The optimum time to assess complete clinical response (CR)
|
|
|
- Vivien Cannon
- 6 years ago
- Views:
Transcription
1 The optimum time to assess complete clinical response (CR) following chemoradiation (CRT) using mitomycin C (MMC) or Cisplatin (CisP) with or without Maintenance CisP/5FU in squamous cell carcinoma of the anus: Results of ACT II Dr Rob Glynne-Jones on behalf of the NCRI ACT II Trial Management Group and Investigators ASCO, Chicago, June Abstract ID: 4004 Cancer Research UK grant number: C444/A628 ISRCTN number: Funder Sponsor
2 ACT II Objectives To evaluate in a factorial design whether chemoradiation using CisP or MMC produces a higher complete response rate maintenance therapy (5FU/CisP) will improve local control /prolong survival by preventing or delaying disease dissemination Accrual patients randomised Jun 01 Dec 08 Median follow-up - 5 years
3 ACT II Factorial Design Chemoradiation Comparison MMC 5FU CRT No maintenance MMC 5FU CRT +Maintenance versus CisP 5FU CRT No maintenance CisP 5FU CRT +Maintenance MMC N=472 CisP N=468
4 ACT II Factorial Design Maintenance Comparison MMC 5FU CRT No maintenance CisP 5FU CRT No maintenance No Maint N=446 versus MMC 5FU CRT Maintenance CisP 5FU CRT Maintenance Maint N=448
5 Chemoradiation Regimens RT week 5FU MMC mg/m 2 d1-4 & hour continuous iv infusion 12mg/m 2 d1 only iv bolus, max single dose 20 mg 6 RT week 5FU CisP mg/m 2 d1-4 & hour continuous iv infusion 60mg/m 2 d1 & 29 iv infusion 6
6 ACT II Response Assessments From start of CRT 11 weeks - ie 4 wks after end of CRT DRE +/- EUA 18 weeks - ie weeks post CRT and pre-maintenance DRE +/- EUA 26 weeks - ie post maintenance 4 wks DRE +/- EUA plus abdo-pelvic CT scan, chest X-ray
7 ACT II Radiotherapy 50.4 Gy 28 daily fractions 5 ½ weeks Two-phase technique Both phases planned simultaneously
8 Tumour Stage MMC (472) CisP (468) T stage T1 T2 49% (232) 54% (254) T3 T4 48% (225) 44% (205) TX N Stage Node negative 63% (297) 62% (290) Node positive 32% (150) 33% (155) NX 25 23
9 Response at 26 weeks Patients with response data (863) MMC (432/472) CisP (431/468) CR primary 90% 90% CR N0 83% (358) 84% (362) CR N+ 3% (15) 3% (12) CR Nx 4% (18) 3% (12) PR 3% (14) 6% (24) SD 1% (5) 1% (6) PD 5% (22) 3% (15) P=0.66
10 Missed Response Assessment at 26 weeks Reason excluded N = 77 Death 23 Progression /salvage surgery 8 Too unwell 5 Assessment inconclusive 2 Did not attend 12 Not assessed 25 Not known 2
11 CR at 26 weeks Difference (95% CI) P value MMC CisP 83% (358/432) No Maint 82% (337/409) 84% (362/431) Maint 85% (348/410) +1% (-3.8 to 6.1) p = % (-2.6 to 7.5) p = 0.34
12 Timing of CR Assessment (691 pts with data at all 3 time-points) Wk Pts with CR CR rate% MMC CisP Absolute risk difference 7.1% (-0.1, +14.5) p= % (-7.9, +4.8) p= % (-6.3, +4.5) p=0.74 HR (95% CI) (CR vs not CR) PFS OS 0.71 (0.53, 0.95) p= (0.38, 0.71) p< (0.15, 0.29) p< (0.49, 0.99) p= (0.34, 0.70) p< (0.15, 0.31) p<0.001
13 ACT II Compliance & Toxicity Radiotherapy 92% MMC vs 90% CisP - total dose 50.4Gy ~3% >7 d interruptions Chemotherapy - weeks 1 & 5 75% MMC vs 72% CisP full dose weeks 1 & 5 Acute toxicity 58% MMC vs 60% CisP Grade 3 13% MMC vs 12% CisP Grade 4 71% MMC vs 72% CisP combined Grade 3/4
14 PFS -free survival MMC vs CisP comparison 74% 73%
15 PFS-free survival CR vs Not CR week 11 80% 72%
16 PFS free-survival CR vs Not CR week 26 83% 45%
17 Overall Survival CR vs Not CR week 26 93% 61%
18 ACT II Conclusions Excellent CR rate at 6 months - 83% v 84% 60% of pts not in CR at 11 weeks achieved CR at 26 weeks. We recommend assessment at 26 weeks in future trials
19 NCCN Guidelines for follow-up version 2, Re-evaluation with DRE at 8-12 weeks after CRT Classify as CR or persistent disease or progressive disease Persistent disease - watch closely for 4 weeks to see if further regression Progressive disease - requires histologic confirmation
20 ACT II 59 Participating Sites Aberdeen Royal Infirmary Maidstone General Hospital Royal Shrewsbury Hospital Addenbrookes Hospital Mount Vernon Hospital Royal South Hants Hospital King's Lynn New Cross Hospital Royal Surrey County Hospital Peterborough Ninewells Hospital Royal Sussex County Hospital Beatson Oncology Centre North Middlesex Hospital Scunthorpe General Belvoir Park Hospital North Staffordshire Royal Infirmary Singleton Hospital Berkshire Cancer Centre North Wales Cancer Treatment Centre St Bartholomew's Bristol Oncology Centre Northampton General Hospital St Georges Hospital Charing Cross Hospital Milton Keynes St Mary's Hospital Cheltenham General Hospital Nottingham City Hospital St Thomas' Hospital Christie Hospital Princess Royal Hospital Diana Princes of Wales Hosp Churchill Hospital Queen Elizabeth Hospital Torbay Hospital Clatterbridge Centre for Oncology Birmingham Heartlands University College Hospital Cookridge Hospital Good Hope Velindre Hospital Cumberland Infirmary Walsall Walsgrave Hospital Derbyshire Royal Infirmary Raigmore Hospital Warwick Derriford Hospital Royal Cornwall Hospital Western General Hospital Ipswich Hospital Royal Devon & Exeter Hospital Weston Park Hospital James Cook University Hospital Royal Marsden Lincoln County Hospital Royal Preston Hospital
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: James RD, Glynne-Jones R, Meadows HM, et al.
Rob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Prague July 2016 State of the art: Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre Aim to discuss Background The trials
Clinical Oncology UK Workforce Report 2012 Faculty of Clinical Oncology
www.rcr.ac.uk Clinical Oncology UK Workforce Report 2012 Faculty of Clinical Oncology www.rcr.ac.uk Contents Foreword 3 1. Introduction and objectives 4 2. Census methodology 5 3. UK clinical oncology
ESMO Preceptorship Programme, Colorectal Cancer, Vienna
State of the art multimodal treatment of anal cancer ESMO Preceptorship Programme, Colorectal Cancer, Vienna Rob Glynne-Jones Mount Vernon Centre for Cancer Treatment Disclosures: last 5 years Speaker:
A national dosimetric audit of VMAT and Tomotherapy in the UK
A national dosimetric audit of VMAT and Tomotherapy in the UK Catharine Clark 1,2,3, M Hussein 1,4, Y Tsang 3,5, D Wilkinson 3,5, R Thomas 2, J Snaith 2, C Gouldstone 2, G Bass 2, S Bolton 6,7, A Nisbet
Carcinoma del Canale Anale. Approcci RadioChemioterapici. Antonino De Paoli.. Oncologia Radioterapica, CRO Aviano.
Carcinoma del Canale Anale Approcci RadioChemioterapici Antonino De Paoli.. Oncologia Radioterapica, CRO Aviano. Anal Cancer Epidemiology and Risk Factors Uncommon Disease; 2-4% of all GI Tumors Increasing
plasma MATCH Andrew Wardley,
in partnership with plasma MATCH A multiple parallel cohort, open-label, multi-centre phase IIa clinical trial of circulating tumour DNA screening to direct targeted therapies in patients with advanced
Rob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Anal Cancer Valencia May 2018 Standard of care for anal squamous cancer Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures: last 5 years Speaker: Roche, Merck Serono,
Travel times and cancer. Impact of travel time on rates of treatment with radiotherapy
Travel times and cancer Impact of travel time on rates of treatment with radiotherapy About Public Health England Public Health England exists to protect and improve the nation s health and wellbeing,
Clinical Oncology UK Workforce Census Report 2013 Faculty of Clinical Oncology
www.rcr.ac.uk Clinical Oncology UK Workforce Census Report 2013 Faculty of Clinical Oncology www.rcr.ac.uk Contents Foreword 3 1. Introduction and methodology 4 2. UK clinical oncology workforce overview
PAMPERING THERAPY. FB 12p PamperingTherapy PT/09/2018.indd 1 25/09/ :56
PAMPERING THERAPY www.lgfb.co.uk FB 12p PamperingTherapy PT/09/2018.indd 1 25/09/2018 13:56 The workshop changed my life around and showed how I could look like the me I used to be, not the me who happens
ANNUAL REPORT ON PANCREAS AND ISLET TRANSPLANTATION
ANNUAL REPORT ON PANCREAS AND ISLET TRANSPLANTATION REPORT FOR 2014/2015 (1 APRIL 2005 31 MARCH 2015) PUBLISHED SEPTEMBER 2015 PRODUCED IN COLLABORATION WITH NHS ENGLAND - 1 - Contents 1 Executive Summary...
PD REHAB Trial Update. Cally Rick 8 th June 2010
PD REHAB Trial Update Cally Rick 8 th June 2010 PD REHAB Randomised controlled trial to assess the clinical- and cost-effectiveness of physiotherapy and occupational therapy in Parkinson's disease. PD
ANNUAL REPORT ON PANCREAS AND ISLET TRANSPLANTATION
ANNUAL REPORT ON PANCREAS AND ISLET TRANSPLANTATION REPORT FOR 2016/2017 (1 APRIL 2007 31 MARCH 2017) PUBLISHED JULY 2017 PRODUCED IN COLLABORATION WITH NHS ENGLAND - 1 - Contents 1 Executive Summary...
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Cook G, Williams C, Brown JM, et al, on behalf
3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
Locally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
The CREST Trial. Funded by Cancer Research UK and developed by the National Cancer Research Institute
The CREST Trial A randomised phase III study of stenting as a bridge to surgery in obstructing colorectal cancer. Results of the UK ColoRectal Endoscopic Stenting Trial (CREST). Funded by Cancer Research
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology
The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies
National Haemoglobinopathy Registry. Annual Report 2017/18
National Haemoglobinopathy Registry Annual Report 2017/18 National Haemoglobinopathy Registry Annual Report (2017/18) Compiled by Mark Foster MDSAS 3 1 Introduction CHAPTER 1 The 2017/18 Annual Report
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
Vascular access. The KidneyCare Audit
Vascular access The KidneyCare Audit Renal National Service Framework The challenge of vascular access Standard 3 All children, young people and adults with established renal failure are to have timely
Eligibility, patient pathway & treatment. Amy Campbell Clinical Trial Coordinator
Eligibility, patient pathway & treatment Amy Campbell Clinical Trial Coordinator Trial design Eligible patients consenting to OPTIMA 4500 patients 100 UK sites 4 years recruitment Randomisation 2250 2250
National Haemoglobinopathy Registry. Annual Report 2015/16. mdsas
National Haemoglobinopathy Registry Annual Report 2015/16 mdsas National Haemoglobinopathy Registry Annual Report (2015/16) 3 1 Introduction CHAPTER 1 This 2015/16 data update follows the same format as
Radiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department
Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly
Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT
Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center Disclosure Consulting
RECTAL CANCER APPARENT COMPLETE RESPONSE (acr) AFTER LONG COURSE CHEMORADIOTHERAPY
COLORECTAL CLINICAL SUBGROUP RECTAL CANCER APPARENT COMPLETE RESPONSE (acr) AFTER LONG COURSE CHEMORADIOTHERAPY Finalised by: Dr Simon Gollins Mr Andrew Renehan Dr Mark Saunders Mr Nigel Scott Dr Shabbir
POST SHOW REPORT EXCEL JUNE 6 & 7 LONDON HEAD & NECK GASTROINTESTINAL RUNNING ALONGSIDE DIAGNOSTIC SURGICAL REHABILITATION BRAIN STIMULATION
MAIN SPONSOR & 7 JUNE EXCEL LONDON HEAD & NECK GASTROINTESTINAL LUNG POST SHOW REPORT PART OF MEDICAL RUNNING ALONGSIDE DIAGNOSTIC SURGICAL REHABILITATION BRAIN STIMULATION PARTNERS 1, We had a great show
Carcinoma del retto: Highlights
Carcinoma del retto: Highlights Stefano Cordio Struttura Complessa di Oncologia Medica ARNAS Garibaldi Catania Roma 17 Febbraio 2018 Disclosures Advisory Committee, research funding and speakers bureau
Combined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
ANAL CANCER Updated May 2016 by Dr. Daniel Yokom (PGY-5 Medical Oncology Resident, University of Toronto)
ANAL CANCER Updated May 2016 by Dr. Daniel Yokom (PGY-5 Medical Oncology Resident, University of Toronto) Reviewed by Dr. Lee-Ying (Staff Medical Oncologist, University of Calgary), Dr. Kzyzanowska (Staff
BASIL Trials. Professor Andrew Bradbury. Chief Investigator University of Birmingham, UK
BASIL Trials Professor Andrew Bradbury Chief Investigator University of Birmingham, UK BASIL-1 Trial 2005 Still the only RCT! NIHR HTA funding 1998 Between 1999 and 2003 452 SLI patients randomised : Bypass
Two Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
Advances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
Dr Roopinder Gillmore July 2017
Dr Roopinder Gillmore July 2017 Resectable Borderline / locally advanced Metastatic 15-20% 15-20% 60-70% 22-28 months 9-15 months 6-12 months Does the patient have resectable disease?? Definitely not
Where are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy
Which Treatment Approach is Most Appropriate for Primary Therapy of Gastric Cancer: Neoadjuvant Chemotherapy Joseph Chao, M.D. Assistant Clinical Professor Department of Medical Oncology & Therapeutics
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
Radical Chemo-Radiotherapy for Oesophageal Cancer: An audit of dose-fractionation schedules and timeliness of treatment
Radical Chemo-Radiotherapy for Oesophageal Cancer: An audit of dose-fractionation schedules and timeliness of treatment Dr L Dixon and Dr J Wadsley Department of Clinical Oncology, Weston Park Hospital,
Update on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
National cataract surgery survey : a report of the results of the clinical outcomes
1336 Moorfields Eye Hospital, London EC1V 2PD P Desai A Reidy Institute of Ophthalmology, University College London, London EC1V 9EL D C Minassian Correspondence to: Miss Desai Accepted for publication
Gastrointestinal Cancer (Non colorectal) Dr Özlem Er
Best of ASCO 2012 İstanbul Gastrointestinal Cancer (Non colorectal) Dr Özlem Er Gastrointestinal Cancer (Non colorectal) LBA 4000: A Randomised Multi-centre Trial of Epirubicin, Oxaliplatin, and Capecitabine
14 January Dear Endometriosis Centre Lead
14 January 2017 Dear Endometriosis Centre Lead Thank you for your continued support of the Endometriosis Centres Project. With this letter is the summary of data from all the centres for 2016 as we have
Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
Chemotherapy in Mesothelioma Project. ChiMP. Mick Peake, Jill Lemon, Liz Darlison, Jeremy Steele, Richard Stephens, Paul Taylor, Sally Moore
Chemotherapy in Mesothelioma Project ChiMP Mick Peake, Jill Lemon, Liz Darlison, Jeremy Steele, Richard Stephens, Paul Taylor, Sally Moore March 2011 Page 1 of 33 Table of contents 1. Introduction 4 Background
Merck Merck response to NICE ACD: Cetuximab in the treatment of LA SCCHN: 26 th February 2007
response to NICE ACD: Cetuximab in the treatment of LA SCCHN: 26 th February 2007 NICE Single Technology Appraisal of cetuximab for the treatment of locally advanced squamous cell carcinoma of the head
Sentinel Stroke National Audit Programme (SSNAP) Based on stroke patients admitted to hospital for thrombectomy between April 2016 and March 2017
Thrombectomy Sentinel Stroke National Audit Programme (SSNAP) Thrombectomy Report for April 2016 - March 2017 National results July 2017 Based on stroke patients admitted to hospital for between April
HYPERTHERMIA in CERVIX and VAGINA CANCER. J. van der Zee
HYPERTHERMIA in CERVIX and VAGINA CANCER J. van der Zee ESTRO 2006 Deep hyperthermia in Rotterdam HYPERTHERMIA in CERVIX and VAGINA CANCER ESTRO 2006 Hyperthermia and radiotherapy in primary advanced cervix
The case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
National Peer Review Report: Sarcoma Cancer Services Report 2012/2013
National Peer Review Programme National Peer Review Report: Sarcoma Cancer Services Report 2012/2013 www.nationalpeerreview.nhs.uk Sarcoma MDT Overall Performance All 15 services reviewed against the 36
Jemal A, Siegel R, Ward E, et al: Cancer statistics, CA: Cancer J Clin 59(4):225-49, 2009
Ovarian cancer 2010-22,500 cases diagnosed per year in the United States and 16,500 deaths per year1. - Most patients are diagnosed in late stages; no screening test exists. - Pathology: 4 different types
Author's response to reviews
Author's response to reviews Title: Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: A randomised study of sequential weekly versus
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
Principal Treatment Centres What do the data say for childhood cancer?
Principal Treatment Centres What do the data say for childhood cancer? Charles Stiller National Registry of Childhood Tumours (NRCT) Childhood Cancer Research Group (CCRG) Children s Cancer and Leukaemia
RECTAL CANCER CLINICAL CASE PRESENTATION
RECTAL CANCER CLINICAL CASE PRESENTATION Francesco Sclafani Medical Oncologist, Clinical Research Fellow The Royal Marsden NHS Foundation Trust, London, UK esmo.org Disclosure I have nothing to declare
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
receive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
Short Study Report for Health Authorities
the Active Title of the Study Randomised trial of single agent doxorubicin versus doxorubicin plus ifosfamide in the first line treatment of advanced or metastatic soft tissue sarcoma Investigators & Study
Breast Cancer Radiotherapy: Clinical challenges in 2011 from a European Perspective. Dr DA WHEATLEY CONSULTANT ONCOLOGIST ROYAL CORNWALL HOSPITAL
Breast Cancer Radiotherapy: Clinical challenges in 2011 from a European Perspective Dr DA WHEATLEY CONSULTANT ONCOLOGIST ROYAL CORNWALL HOSPITAL Radiotherapy in Early Breast Cancer Why do we do it? Who
Bladder Preservation Strategies for Muscle Invasive Bladder Cancer
Bladder Preservation Strategies for Muscle Invasive Bladder Cancer Jeff M. Michalski, MD, MBA, FACR, FASTRO The Carlos A. Perez Distinguished Professor of Radiation Oncology Department of Radiation Oncology
National Comparative Audit of Blood Transfusion Audit of Red Cell & Platelet Transfusion in Adult Haematology Patients.
National Comparative Audit of Blood Transfusion 2016 Audit of Red Cell & Platelet Transfusion in Adult Haematology Patients South West RTC Why was this audit necessary? Up to 65% of all platelet transfusions
Adjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
original article Cisplatin plus versus for Biliary Tract Cancer Juan Valle, M.D., Harpreet Wasan, M.D., Daniel H. Palmer, M.D., Ph.D., David Cunningham, M.D., Alan Anthoney, M.D., Anthony Maraveyas, M.D.,
Rob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Barcelona October 2017 Interventional radiology and stereotactic radiotherapy Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures: last 5 years Speaker:
Pre- Versus Post-operative Radiotherapy
Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: James ND, Hussain SA, Hall E, et al. Radiotherapy with or without
Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL):
Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial H. Eghbali, P.
GASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
Cochrane metaanalysis 5 year OS Intent to treat
RADICAL CYSTECTOMY IS THE ONLY EFFECTIVE TREATMENT FOR PATIENTS WITH OPERABLE MUSCLE INVASIVE BLADDER CANCER The Con position Scott Tyldesley Radiation Oncology, Vancouver Centre, BC Cancer Agency Cochrane
EGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
Laryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation
1 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
The role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
Neodjuvant chemotherapy
Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy
BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GICART Gastrointestinal
Combined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
Adjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
INMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
FoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer
Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer Emily Chan, Qian Shi, Julio Garcia-Aguilar, Peter Cataldo, Jorge
New Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor
New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK
Lead Group Log Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Cervical Cancer treatment Treatment planning should be made on a multidisciplinary
Life after CHIPS: CHIPS+ and AALPHI update. Marthe Le Prevost AALPHI Research Nurse MRC Clinical Trials Unit at UCL
Life after CHIPS: CHIPS+ and AALPHI update Marthe Le Prevost AALPHI Research Nurse MRC Clinical Trials Unit at UCL Talk outline CHIPS+ introduction progress to date AALPHI recruitment update cohort characteristics
Chapter 10: Serum Calcium, Phosphate and Parathyroid Hormone
Chapter 1: Serum Calcium, Phosphate and Parathyroid Hormone Summary Results for corrected calcium are highly dependent on serum albumin measurement. Units using the BCP method of albumin measurement have
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer
Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer Nobukazu Fuwa 1, Akinori Takada 2 and Takahiro Kato 3 1;Departments of Radiology, Hyogo Ion Beam Medical
Are we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
Pancreatic Cancer Where are we?
Pancreatic Cancer Treatment Approaches & Options Pancreatic Cancer Action Network OUMC 9/22/2016 Russell G. Postier, MD Pancreatic Cancer Where are we? Estimated 2016 data 3% of cancer cases 7% of cancer
RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
The AHEAD Study: Managing anticoagulatedpatients who suffer head injury
AHEAD Study The AHEAD Study: Managing anticoagulatedpatients who suffer head injury Suzanne Mason 1,2, Maxine Kuczawski 1, Matthew Stevenson 1, Dawn Teare 1, Michael Holmes 1, ShammiRamlakhan 1, Steve
De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist
De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to
Research Involving RaDaR: Nephrotic Syndrome - NephroS/ NURTuRE Studies. Liz Colby Project Manager, University of Bristol
Research Involving RaDaR: Nephrotic Syndrome - NephroS/ NURTuRE Studies Liz Colby Project Manager, University of Bristol What is Nephrotic Syndrome? Breakdown of the glomerular filtration barrier Massive
September 10, Dear Dr. Clark,
September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,
Hypofractionated RT in Cervix Cancer. Anuja Jhingran, MD
Hypofractionated RT in Cervix Cancer Anuja Jhingran, MD Hypofractionated RT in Cervix Cancer: Clinicaltrials.gov 919 cervix trials 134 hypofractionated RT trials Prostate, breast, NSCLC, GBM 0 cervix trials
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy
San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy Kathleen C. Horst, M.D. Assistant Professor Department of Radiation Oncology Stanford University The Optimal SEquencing of Adjuvant Chemotherapy